AKT2 and acute myeloid leukemia: These abovementioned findings, together with our gene list enriched with WNT-related molecules and AKT2, AKT3 genes, prompted us to explore the impact of PI3K/AKT/mTOR signaling inhibition in PRL-3 high AML cells in combination with WNT/β-catenin inhibitor.